{"id":"https://genegraph.clinicalgenome.org/r/3b98b141-17ec-4b18-92df-9c5a80cd80eev1.0","type":"EvidenceStrengthAssertion","dc:description":"There is abundant evidence published associating the BRCA2 gene with Fanconi anemia complementation group D1, since the gene-disease relationship was first proposed by Howlett et al. (2002). Multiple case level studies have been performed with FA patients that have variants in the BRCA2 gene. BRCA1, BRIP1, RAD51C, PALB2 have also been established as FA genes in the FA/BRCA DNA repair pathway. Multiple Brca2 deficient mouse models have been established to show consistent phenotypes with FA patients including increased overall tumor incidence, decreased survival and hematopoietic dysfunction. Wildtype BRCA2 cDNA restored mitomycin C (MMC) resistance in patient derived fibroblasts. All of these types of evidence are consistent with a definitive relationship between the BRCA2 gene and Fanconi anemia complementation group D1.","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/3b98b141-17ec-4b18-92df-9c5a80cd80ee","GCISnapshot":"https://genegraph.clinicalgenome.org/r/48faf04b-ffc4-4163-8570-22f5c29c4064","calculatedEvidenceStrength":"Definitive","contributions":[{"id":"https://genegraph.clinicalgenome.org/r/48faf04b-ffc4-4163-8570-22f5c29c4064_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10023","date":"2019-04-19T16:00:00.000Z","role":"Approver"},{"id":"https://genegraph.clinicalgenome.org/r/48faf04b-ffc4-4163-8570-22f5c29c4064_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10023","date":"2020-09-01T00:00:00Z","role":"Publisher"}],"curationReasonDescription":"","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/48faf04b-ffc4-4163-8570-22f5c29c4064_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d1ab6f81-0c8d-4f63-b638-0a34c2d7b38f_proband_score_evidence_line","type":"EvidenceLine","dc:description":"A homozygous splice site mutation in intron 7 of the BRCA2 gene, IVS7+1G-A. Two star variants in ClinVar.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/20e1fb4e-e188-4127-b05d-c328ea2bc6eb","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/15070707","rdfs:label":"Kindred 1 IFAR 129/1","ageType":"AgeAtDiagnosis","ageUnit":"Months","ageValue":26,"detectionMethod":"","firstTestingMethod":"PCR","phenotypes":["obo:HP_0000252","obo:HP_0002023","obo:HP_0000957","obo:HP_0004808","obo:HP_0001511","obo:HP_0001508"],"previousTesting":false,"previousTestingDescription":"","secondTestingMethod":"Sanger sequencing","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/d1ab6f81-0c8d-4f63-b638-0a34c2d7b38f_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/15070707","allele":{"id":"https://genegraph.clinicalgenome.org/r/a8e11ba9-152b-4cd4-9d28-9c79fa4cbfee","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000059.3(BRCA2):c.631+2T>G","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/9349"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"}}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/ecd9f68f-bf96-4d5c-a9f6-18e9a0de266a_proband_score_evidence_line","type":"EvidenceLine","dc:description":"Homozygosity for an intron 19 mutation, IVS19-1G-A, in the BRCA2 gene. This mutation results in deletion of 12 nucleotides or 4 amino acids in exon 20. Two star variants in ClinVar with 13 different submitters.","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/cfbca298-54f0-448a-8cf2-2f520d39ad21","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12065746","rdfs:label":"HSC62","ageType":"https://genegraph.clinicalgenome.org/r/","ageUnit":"https://genegraph.clinicalgenome.org/r/","detectionMethod":"They sequenced BRCA1 and BRCA2 in cells derived from FA-B and FA-D1 patients (Table 1 and Fig. 1A).","firstTestingMethod":"PCR","phenotypeFreeText":"Fanconi anemia","phenotypes":"obo:HP_0005528","previousTesting":false,"previousTestingDescription":"","secondTestingMethod":"Sanger sequencing","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/ecd9f68f-bf96-4d5c-a9f6-18e9a0de266a_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12065746","allele":{"id":"https://genegraph.clinicalgenome.org/r/db0ff9f2-4056-465c-bb27-7bc39ff41d2c","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000059.3(BRCA2):c.8488-1G>A","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/38164"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"}}}],"specifiedBy":"GeneValidityProbandARNonNullCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/7ef66f38-45c2-468f-ab09-d0fb6bd9a1bd_proband_score_evidence_line","type":"EvidenceLine","dc:description":"A splice site mutation in intron 7 of the BRCA2 gene, IVS7+1G-A, in compound heterozygosity with a premature termination mutation (Tyr1894Ter). One two star variant and one three star variant in ClinVar.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/9d7775e3-b909-4c10-9df5-15aea0e3846a","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/15070707","rdfs:label":"Kindred 3 632/1","ageType":"AgeAtDiagnosis","ageUnit":"Months","ageValue":36,"detectionMethod":"","firstTestingMethod":"PCR","phenotypes":["obo:HP_0004808","obo:HP_0004322","obo:HP_0001511","obo:HP_0000957","obo:HP_0008780"],"previousTesting":false,"previousTestingDescription":"","secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/7ef66f38-45c2-468f-ab09-d0fb6bd9a1bd_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/15070707","allele":[{"id":"https://genegraph.clinicalgenome.org/r/06284d4b-f6c4-429b-a1d9-75e552377189","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000059.3(BRCA2):c.631+1G>A","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/9348"}},{"id":"https://genegraph.clinicalgenome.org/r/ce3a0830-002a-46a0-bea8-bc2b3362e343","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000059.3(BRCA2):c.5682C>G (p.Tyr1894Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/37989"}}],"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"}}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/48faf04b-ffc4-4163-8570-22f5c29c4064_seg_el","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d8c12193-2eed-4c58-b88a-299ee9a48a29_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/14670928","rdfs:label":"Kindred 2","estimatedLodScore":0.6,"family":{"id":"https://genegraph.clinicalgenome.org/r/d8c12193-2eed-4c58-b88a-299ee9a48a29","type":"Family","rdfs:label":"Kindred 2","ethnicity":{"id":"cg:NotHispanicOrLatino"},"member":{"id":"https://genegraph.clinicalgenome.org/r/bd5194c4-8f94-450c-9449-cf610490cb96","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/14670928","rdfs:label":"Kindred 2 Sibling 1","ageType":"AgeAtReport","ageUnit":"Months","ageValue":6,"detectionMethod":"","ethnicity":{"id":"cg:NotHispanicOrLatino"},"firstTestingMethod":"PCR","phenotypes":["obo:HP_0004808","obo:HP_0001518","obo:HP_0000252","obo:HP_0002667"],"previousTesting":false,"previousTestingDescription":"","secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/913d864e-0ea9-4f03-8f4d-6aa7aee217bf_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/14670928","allele":[{"id":"https://genegraph.clinicalgenome.org/r/43a502a1-c643-4728-99dc-7d8a60c538a0","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000059.3(BRCA2):c.7529T>C (p.Leu2510Pro)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/9345"}},{"id":"https://genegraph.clinicalgenome.org/r/7181c478-8b67-4877-811f-7ff834fe4f13","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000059.3(BRCA2):c.4648G>T (p.Glu1550Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/9344"}}],"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"}}}},"meetsInclusionCriteria":false,"phenotypeFreeText":"","phenotypeNegativeAlleleNegative":0,"phenotypePositiveAllelePositive":2,"phenotypes":["obo:HP_0002667","obo:HP_0004808","obo:HP_0000252","obo:HP_0001518","obo:HP_0006727"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/bd5194c4-8f94-450c-9449-cf610490cb96"}},{"id":"https://genegraph.clinicalgenome.org/r/e3a6e078-56df-479b-83a5-292e7852e2ae_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12065746","rdfs:label":"EUFA423","estimatedLodScore":0.62,"family":{"id":"https://genegraph.clinicalgenome.org/r/e3a6e078-56df-479b-83a5-292e7852e2ae","type":"Family","rdfs:label":"EUFA423","ethnicity":{"id":"https://genegraph.clinicalgenome.org/r/"},"member":{"id":"https://genegraph.clinicalgenome.org/r/72bd1d77-1afb-487f-aa70-7c45ef86666a","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12065746","rdfs:label":"EUFA423","ageType":"https://genegraph.clinicalgenome.org/r/","ageUnit":"https://genegraph.clinicalgenome.org/r/","detectionMethod":"They sequenced BRCA1 and BRCA2 in cells derived from FA-B and FA-D1 patients (Table 1 and Fig. 1A).","firstTestingMethod":"PCR","phenotypeFreeText":"Fanconi anemia","phenotypes":"obo:HP_0005528","previousTesting":false,"previousTestingDescription":"","secondTestingMethod":"Sanger sequencing","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/d9c2a93d-29f9-4932-be5f-cfb7d85e9db4_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12065746","allele":[{"id":"https://genegraph.clinicalgenome.org/r/0eaf0453-0d8c-4132-9e20-6c3c94606c42","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000059.3(BRCA2):c.7464_7465insTA (p.Asp2489Terfs)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/254605"}},{"id":"https://genegraph.clinicalgenome.org/r/bbcce500-f701-400d-94b6-f08dd8557688","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000059.3(BRCA2):c.9672dupA (p.Tyr3225Ilefs)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/126217"}}],"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"}}}},"meetsInclusionCriteria":false,"phenotypeFreeText":"Fanconi anemia","phenotypeNegativeAlleleNegative":5,"phenotypePositiveAllelePositive":1,"phenotypes":"obo:HP_0005528","proband":{"id":"https://genegraph.clinicalgenome.org/r/72bd1d77-1afb-487f-aa70-7c45ef86666a"}},{"id":"https://genegraph.clinicalgenome.org/r/c723bc92-b432-41ff-a79a-7b7e80346b15_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/14670928","rdfs:label":"Kindred 1","estimatedLodScore":0.6,"family":{"id":"https://genegraph.clinicalgenome.org/r/c723bc92-b432-41ff-a79a-7b7e80346b15","type":"Family","rdfs:label":"Kindred 1","ethnicity":{"id":"cg:NotHispanicOrLatino"},"member":{"id":"https://genegraph.clinicalgenome.org/r/6173def9-c9e9-415e-8197-1c5ee20da89f","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/14670928","rdfs:label":"Kindred 1 Sibling 2","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":15,"detectionMethod":"","ethnicity":{"id":"cg:NotHispanicOrLatino"},"firstTestingMethod":"PCR","phenotypes":["obo:HP_0002885","obo:HP_0000957","obo:HP_0002667","obo:HP_0000252"],"previousTesting":false,"previousTestingDescription":"","secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/f787ecee-0c1a-4798-8f9b-17773d1726c8_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/14670928","allele":[{"id":"https://genegraph.clinicalgenome.org/r/c3935175-4f3b-4df2-a940-7a9d342d5b8a","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000059.3(BRCA2):c.658_659delGT (p.Val220Ilefs)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/9342"}},{"id":"https://genegraph.clinicalgenome.org/r/1faff643-57c3-4b42-a4c3-6d879682fca4","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000059.3(BRCA2):c.8219T>A (p.Leu2740Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/9343"}}],"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"}}}},"meetsInclusionCriteria":false,"phenotypeFreeText":"","phenotypeNegativeAlleleNegative":0,"phenotypePositiveAllelePositive":2,"phenotypes":["obo:HP_0002667","obo:HP_0000252","obo:HP_0002885","obo:HP_0000957"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/6173def9-c9e9-415e-8197-1c5ee20da89f"}}],"specifiedBy":"GeneValiditySegregationEvidenceCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/d9c2a93d-29f9-4932-be5f-cfb7d85e9db4_proband_score_evidence_line","type":"EvidenceLine","dc:description":"Compound heterozygosity with an insertion of AT at nucleotide 7691 in exon 15, and the other was an insertion of A at nucleotide 9900 in exon 27. Both mutations created frameshifts that were predicted to encode carboxy-terminal truncated BRCA2 proteins. Both variants are three star pathogenic variants in ClinVar, reviewed by ENIGMA for Breast-ovarian cancer, familial 2.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/72bd1d77-1afb-487f-aa70-7c45ef86666a"}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/d57b89ad-a200-478f-8553-476a95803f29_proband_score_evidence_line","type":"EvidenceLine","dc:description":"Compound heterozygosity for 2 BRCA2 mutations: 7235G-A in exon 13 and 5837TC to AG in exon 11. One two star and one three star pathogenic variants in ClinVar.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/95e31d70-124b-476f-bde9-2f30f24bb82f","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12065746","rdfs:label":"EUFA579","ageType":"https://genegraph.clinicalgenome.org/r/","ageUnit":"https://genegraph.clinicalgenome.org/r/","detectionMethod":"They sequenced BRCA1 and BRCA2 in cells derived from FA-B and FA-D1 patients (Table 1 and Fig. 1A).","firstTestingMethod":"PCR","phenotypeFreeText":"Fanconi anemia","phenotypes":"obo:HP_0005528","previousTesting":false,"previousTestingDescription":"","secondTestingMethod":"Sanger sequencing","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/d57b89ad-a200-478f-8553-476a95803f29_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12065746","allele":[{"id":"https://genegraph.clinicalgenome.org/r/be26504a-a1a2-4e17-89ab-d2c6383fdce3","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000059.3(BRCA2):c.7007G>A (p.Arg2336His)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/38077"}},{"id":"https://genegraph.clinicalgenome.org/r/1dec4313-ef47-4284-be52-a2c8a0e9f14e","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000059.3(BRCA2):c.5609_5610delTCinsAG (p.Phe1870Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/51890"}}],"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"}}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/f787ecee-0c1a-4798-8f9b-17773d1726c8_proband_score_evidence_line","type":"EvidenceLine","dc:description":"Compound heterozygosity for mutations in the BRCA2 gene: a 2-bp deletion in exon 8 (886delGT), and an 8447T-A transversion in exon 18, resulting in a leu2740-to-ter substitution (L2740X). Both variants are three star pathogenic variants in ClinVar, reviewed by ENIGMA for Breast-ovarian cancer, familial 2.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/6173def9-c9e9-415e-8197-1c5ee20da89f"}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/913d864e-0ea9-4f03-8f4d-6aa7aee217bf_proband_score_evidence_line","type":"EvidenceLine","dc:description":"Compound heterozygosity for mutations in the BRCA2 gene: a 4876G-T transversion, resulting in a glu1550-to-ter (E1550X) substitution, and a 7757T-C transition, resulting in a leu2510-to-pro substitution (L2510P). One three star and one two star variants in ClinVar.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/bd5194c4-8f94-450c-9449-cf610490cb96"}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":12},{"id":"https://genegraph.clinicalgenome.org/r/48faf04b-ffc4-4163-8570-22f5c29c4064_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/48faf04b-ffc4-4163-8570-22f5c29c4064_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/29463537-2867-46a7-b4e9-ca61b376fa05","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/7bbfeaf1-010f-4340-a063-7ea5bd3df1bd","type":"Finding","dc:description":"Low numbers of hematopoietic colony-forming cells (CFCs) were noted in Brca2 Del27/Del27 mice. A high incidence of spontaneous chromosomal instability was observed in Brca2 Del27/Del27 bone marrow (BM) cells. A very severe hematopoietic syndrome was observed in irradiated Brca2 Del27/Del27 mice. Conventional BM competition experiments showed a marked repopulation defect in Brca2 Del27/Del27 hematopoietic stem cells (HSCs), compared to wild-type HSCs. They also reported a very significant proliferation defect in Brca2 Del27/Del27 HSCs maintained in their natural physiological environment.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16859999","rdfs:label":"Hematopoietic Dysfunction in a FA-D1 Mouse Model","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/8f46db6e-caa5-4c00-a083-29b78bb0254d","type":"EvidenceLine","dc:description":"Showed high incidence of cancer in mice with hypomorphic mutations in Brca2, but not specific in mouse hematopoiesis.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/39c49297-541d-4004-92fc-8ad943a167e1","type":"Finding","dc:description":"These homozygous Brca2-mutant mice have a significantly increased overall tumor incidence and decreased survival compared with their heterozygous littermates.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11861370","rdfs:label":"Cancer Susceptibility of Mice with Homozygous Brca2 Deletion","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/33fbc98f-e115-453a-aa0f-16cffc877ea5","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ee785f78-3ce7-4f28-878d-540f64434c85","type":"Finding","dc:description":"Functional complementation of FANCD1 fibroblasts with wildtype BRCA2 cDNA restored mitomycin C (MMC) resistance.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12065746","rdfs:label":"Wildtype BRCA2 cDNA restored mitomycin C (MMC) resistance","demonstrates":{"id":"cg:PhenotypeRescue"}}],"specifiedBy":"GeneValidityPatientCellRescueCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":4},{"id":"https://genegraph.clinicalgenome.org/r/48faf04b-ffc4-4163-8570-22f5c29c4064_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5a2a0010-b49b-421a-b2ad-bcca06c09894","type":"EvidenceLine","dc:description":"0.5 point for each genes (BRCA1, PALB2, BRIP1 and RAD51C)","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/98c0d71f-2f95-401f-9bc8-f744ba33d38d","type":"Finding","dc:description":"BRCA1, BRCA2, BRIP1, RAD51C and PALB2 have been established as FA genes. BRCA2 protein stability and localization is regulated by PALB2. BRCA2 binds RAD51 and potentiates recombinational DNA repair by promoting assembly of RAD51 onto single-stranded DNA (ssDNA).","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29376519","rdfs:label":"BRCA1, BRIP1, RAD51C, PALB2 have been established as FA gene","demonstrates":{"id":"cg:BiochemicalFunctionA"}}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":6}],"evidenceStrength":"Definitive","sequence":250,"specifiedBy":"GeneValidityCriteria6","strengthScore":18,"subject":{"id":"https://genegraph.clinicalgenome.org/r/Hj-tgTAjwRI","type":"GeneValidityProposition","disease":"obo:MONDO_0011584","gene":"hgnc:1101","modeOfInheritance":"obo:HP_0000007"},"version":"1.0","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_48faf04b-ffc4-4163-8570-22f5c29c4064-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}